LABELS · 4410582a-a5f3-429f-a7ca-5c17fb5560bf

Pomalyst

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-02-26
Captured: 2026-09-09T23:37:44.904352+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning EMBRYO-FETAL TOXICITY • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects ( 4 , 5.1 , 8.1 ). • For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception ( 5.1 , 8.3 ). POMALYST is available only through a restricted program called PS-Pomalidomide REMS ( 5.2 ). VENOUS AND ARTERIAL THROMBOEMBOLISM • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended ( 5.3 ). Embryo-Fetal Toxicity • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting POMALYST treatment. • Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping POMALYST treatment [see Contraindications (4) , Warnings and Precautions (5.1) and Use in Specific Populations (8.1 , 8.3) ]. POMALYST is only available through a restricted distribution program called PS-Pomalidomide REMS [see Warnings and Precautions (5.2) ]. Information about PS-Pomalidomide REMS is available at www.PS-PomalidomideREMS.com or by calling the REMS Call Center at 1-888-423-5436. Venous and Arterial Thromboembolism • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors [see Warnings and Precautions (5.3) ].

Indications and usage: exact source text

1 INDICATIONS AND USAGE POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Full extracted label fields

application numbers

NDA204026

boxed warning exact

WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM WARNING: EMBRYO-FETAL TOXICITY and VENOUS AND ARTERIAL THROMBOEMBOLISM See full prescribing information for complete boxed warning EMBRYO-FETAL TOXICITY • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe life-threatening birth defects ( 4 , 5.1 , 8.1 ). • For females of reproductive potential: Exclude pregnancy before start of treatment. Prevent pregnancy during treatment by the use of 2 reliable methods of contraception ( 5.1 , 8.3 ). POMALYST is available only through a restricted program called PS-Pomalidomide REMS ( 5.2 ). VENOUS AND ARTERIAL THROMBOEMBOLISM • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Antithrombotic prophylaxis is recommended ( 5.3 ). Embryo-Fetal Toxicity • POMALYST is contraindicated in pregnancy. POMALYST is a thalidomide analogue. Thalidomide is a known human teratogen that causes severe birth defects or embryo-fetal death. In females of reproductive potential, obtain 2 negative pregnancy tests before starting POMALYST treatment. • Females of reproductive potential must use 2 forms of contraception or continuously abstain from heterosexual sex during and for 4 weeks after stopping POMALYST treatment [see Contraindications (4) , Warnings and Precautions (5.1) and Use in Specific Populations (8.1 , 8.3) ]. POMALYST is only available through a restricted distribution program called PS-Pomalidomide REMS [see Warnings and Precautions (5.2) ]. Information about PS-Pomalidomide REMS is available at www.PS-PomalidomideREMS.com or by calling the REMS Call Center at 1-888-423-5436. Venous and Arterial Thromboembolism • Deep venous thrombosis (DVT), pulmonary embolism (PE), myocardial infarction, and stroke occur in patients with multiple myeloma treated with POMALYST. Prophylactic antithrombotic measures were employed in clinical trials. Thromboprophylaxis is recommended, and the choice of regimen should be based on assessment of the patient's underlying risk factors [see Warnings and Precautions (5.3) ].

brand names

Pomalyst

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2b25ef01-5c9e-11e1-b86c-0800200c9a66

generic names

POMALIDOMIDE

4410582a-a5f3-429f-a7ca-5c17fb5560bf

indications and usage exact

1 INDICATIONS AND USAGE POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

indications and usage tables exact

is original packager

true

manufacturer names

Celgene Corporation

matched search terms

sarcoma
myeloma

package ndcs

59572-501-21
59572-501-00
59572-502-21
59572-502-00
59572-503-21
59572-503-00
59572-504-21
59572-504-00

product ndcs

59572-501
59572-502
59572-503
59572-504

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Boxed Warning 2/2025 Warnings and Precautions ( 5.1 , 5.2 ) 2/2025

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

1369718
1369724
1369726
1369728
1369730
1369732
1369734
1369736

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00200.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 305
end exclusive: true
exact text: 1 INDICATIONS AND USAGE POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated dis
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 0

current approval status

not_reconciled

duplicate text group

dup-b5ef0dbd6d91d14bf1a8

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-aa4bd5a9a3e431249afe

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 68
end exclusive: true
exact text: is a thalidomide analogue indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 33

qualifier mentions

context exact
ST is a thalidomide analogue indicated for the treatment of adult patients:
kind
age
polarity
not_inferred
span
end
104
end exclusive
true
exact text
adult patients
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
90

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 105
end exclusive: true
exact text: 1 INDICATIONS AND USAGE POMALYST is a thalidomide analogue indicated for the treatment of adult patients:
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 585
end exclusive: true
exact text: 1 INDICATIONS AND USAGE POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approv
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 0

current approval status

not_reconciled

duplicate text group

dup-13728bc9f4b3dafeecfa

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-ee1f044f672541e0e5af

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 68
end exclusive: true
exact text: is a thalidomide analogue indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 33

qualifier mentions

context exact
with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ).
kind
prior_therapy_or_line
polarity
not_inferred
span
end
360
end exclusive
true
exact text
who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
183
context exact
• in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of c
kind
regimen
polarity
not_inferred
span
end
287
end exclusive
true
exact text
in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and hav
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
108

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 385
end exclusive: true
exact text: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ).
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 106

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 732
end exclusive: true
exact text: have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit i
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 186

current approval status

not_reconciled

duplicate text group

dup-36dd5d1e8f4bb067e3a7

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-6955ca49f415200fd8cc

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 68
end exclusive: true
exact text: is a thalidomide analogue indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 33

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 532
end exclusive: true
exact text: • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative.
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 386

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · approval contingency

application numbers

NDA204026

brand names

Pomalyst

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 819
end exclusive: true
exact text: n 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with d
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 333

current approval status

not_reconciled

duplicate text group

dup-0d40584e09fe3d95c8e2

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-568e2590612abf2b5510

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 619
end exclusive: true
exact text: This indication is approved under accelerated approval based on overall response rate.
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 533

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · approval contingency

application numbers

NDA204026

brand names

Pomalyst

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 966
end exclusive: true
exact text: (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 420

current approval status

not_reconciled

duplicate text group

dup-59137600934c1a68ca85

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-a31ffdeea1a214794ec7

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 766
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ).
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 620

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1286
end exclusive: true
exact text: accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 567

current approval status

not_reconciled

duplicate text group

dup-4f22988c7651e4003ec0

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-de1d5d28a732d67ac982

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 845
end exclusive: true
exact text: is indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 833

qualifier mentions

context exact
MALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two p
kind
age
polarity
not_inferred
span
end
864
end exclusive
true
exact text
adult patients
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
850
context exact
is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
kind
prior_therapy_or_line
polarity
not_inferred
span
end
1069
end exclusive
true
exact text
who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
892
context exact
1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or
kind
regimen
polarity
not_inferred
span
end
977
end exclusive
true
exact text
in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasom
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
798

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 1086
end exclusive: true
exact text: 1.1 Multiple Myeloma POMALYST, in combination with dexamethasone, is indicated for adult patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy.
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 767

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1349
end exclusive: true
exact text: (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 887

current approval status

not_reconciled

duplicate text group

dup-7f0b9043bd29136240d0

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-3514d20917e82f3e1cc9

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 1127
end exclusive: true
exact text: is indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1115

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 1149
end exclusive: true
exact text: 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of:
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1087

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1467
end exclusive: true
exact text: enalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 950

current approval status

not_reconciled

duplicate text group

dup-144c1a9a270244860a73

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-d1d0e62cc3e3114901a4

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 1127
end exclusive: true
exact text: is indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1115

qualifier mentions

context exact
• Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of high
kind
age
polarity
not_inferred
span
end
1166
end exclusive
true
exact text
Adult patients
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
1152

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 1267
end exclusive: true
exact text: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART).
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1150

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · positive indication candidate

application numbers

NDA204026

brand names

Pomalyst

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1529
end exclusive: true
exact text: the last therapy. 1.2 Kaposi Sarcoma POMALYST is indicated for the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and d
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1068

current approval status

not_reconciled

duplicate text group

dup-9100802d26030fa3c7b7

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-37601c0c7e891506095e

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

end: 1127
end exclusive: true
exact text: is indicated
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1115

qualifier mentions

context exact
• Kaposi sarcoma (KS) in adult patients who are HIV-negative.
kind
age
polarity
not_inferred
span
end
1307
end exclusive
true
exact text
adult patients
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
1293

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 1329
end exclusive: true
exact text: • Kaposi sarcoma (KS) in adult patients who are HIV-negative.
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1268

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 10 · approval contingency

application numbers

NDA204026

brand names

Pomalyst

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1587
end exclusive: true
exact text: r the treatment of: • Adult patients with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1130

current approval status

not_reconciled

duplicate text group

dup-f7e4153c3ebcf502e5d2

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-6ee65f876c82edfac4f9

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 1448
end exclusive: true
exact text: This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] .
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1330

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 11 · approval contingency

application numbers

NDA204026

brand names

Pomalyst

classification reasons

approval_contingency_words

clinical review status

pending

content role

approval_contingency

context span

end: 1587
end exclusive: true
exact text: l therapy (HAART). • Kaposi sarcoma (KS) in adult patients who are HIV-negative. This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1249

current approval status

not_reconciled

duplicate text group

dup-d573d827a97a22545c64

extraction review status

automated_candidate_pending_source_review

generic names

POMALIDOMIDE

ind-span-3e3b34d1d30d3666153b

label id

4410582a-a5f3-429f-a7ca-5c17fb5560bf

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

d918de6bede8f776ad4fea2bc639292f8454d9733fbbdfdd7fd4414b6200e571

source defined aliases

abbreviation
MM
definition exact
multiple myeloma
definition span
end
182
end exclusive
true
exact text
multiple myeloma (MM)
label id
4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start
161

source span

end: 1587
end exclusive: true
exact text: Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
label id: 4410582a-a5f3-429f-a7ca-5c17fb5560bf
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 8e795b81be033680ce25f18253f9591faaf236ba5c954fd334d06cbb00108afb
start: 1449

source url

https://api.fda.gov/drug/label.json?search=id%3A%224410582a-a5f3-429f-a7ca-5c17fb5560bf%22

spl effective date

2025-02-26

spl set id

2b25ef01-5c9e-11e1-b86c-0800200c9a66

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice